Guidance

Shingles vaccine (Zostavax®): patient group direction (PGD) template

PGD template to support the national shingles (Zostavax®) vaccination programme for eligible adults.

From:
UK Health Security Agency
Published
14 July 2015
Last updated
11 December 2023 — See all updates

Applies to England

Documents

Shingles vaccine (Zostavax®) PGD template

Ref: UKHSA gateway number GOV-15000

MS Word Document, 177 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Notice of extension of the validity of Zostavax PGD

MS Word Document, 122 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template is to support the administration of shingles (herpes zoster, live) vaccine in accordance with the national shingles (herpes zoster) immunisation programme.

Zostavax PGD version 11.00 is valid from 1 September 2023 and expires on 30 June 2024 and has been optionally extended to 31 October 2024, to coincide with the UK Health Security Agency’s (UKHSA’s) longest dated stock.

Individuals identified as eligible under the inclusion criteria remain so for as long as Zostavax® remains available and clinic stock is in date.

When locally-held stocks are depleted and Zostavax® is no longer available from ImmForm, the authorising manager (as per section 7) should retire this PGD and revert to using the Shingrix® vaccine PGD to vaccinate individuals against shingles.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy or procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

A PGD template for Shingrix® is available to download.

Published 14 July 2015
Last updated 11 December 2023 + show all updates

  1. Added notice of extension of validity.

  2. Added version 11 – see page 2 for change history.

  3. Added v10.00.

  4. Updated date in footer.

  5. Added version 09.00 - see page 2 for change history.

  6. Added version V08.00 - updated as routine review prior to PGD expiry (see document change history).

  7. Revised document to correct inclusion criteria date from 2013 to 2012 and add DOB note.

  8. Updated patient group direction template to allow vaccination from turn of age 70 or 78

  9. Updated patient group direction template valid up to 31 August 2017

  10. Updated PGD to allow for intramuscular administration (in line with the amended product license).

  11. Updated the shingles PGD to include detailed information on the use of the shingles vaccine in immunosuppressed individuals.

  12. First published.

Related content